FHOD1

Across TCGA pan-cancer cohorts, FHOD1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FHOD1 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FHOD1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FHOD1 expression acts as an unfavorable survival marker.

LIHC, SKCM, and SCLC are the cancer types where FHOD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.167	0.547	.001	17	view →
SKCM	OS	Median	II,III,IV	0.303	0.740	.001	15	view →
SCLC	OS	Median	All	0.164	0.661	<.001	6	view →
ESCA	OS	Median	III,IV	0.130	0.574	.011	6	view →
LUAD	OS	Median	All	0.429	0.674	.029	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FHOD1–LIHC (DFS)

Open the LIHC breakdown →